Page 49 - MemoriaES-Eng

www.ciberes.org

CIBERES researchers have made important contributions in the diagno-

sis of latent TB infection and TB disease. Molecular techniques are es-
sential tools to improve the control of tuberculosis. These techniques allow the

strains to be differentiated from different clonal origins with greater efficiency.

Main results Publications:

in 2013

• Construction, characterization and preclinical evaluation of MTBVAC, the first
live-attenuated M. tuberculosis-based vaccine to enter clinical trials. A A,
rBueS
Aguilo Ji, gonZAlo-ASenSio J, MArinoVA d, urAngA S, PuenteS e, FernándeZ c, PArrA

A, cArdonA PJ, VilAPlAnA c, AuSinA V, WilliAMS A, clArk S, MálAgA W, guilHot c,
g B, M c. Vaccine. 1 de octubre de 2013. Volumen: 31 Número: 42
icQuelArtíná
Pginas: 4867-73.

• Analysis of mutations in streptomycin-resistant strains reveals a simple and
ó
reliable genetic marker for identification of the Mycobacterium tuberculosis
Beijing genotype. V c, A l, V MA, P c, B S, g
illellASriStiMuñoitoriArAtlAncoArcíAde
ViedMA d, doMíngueZ J, SAMPer S, AínSA JA. Journal of clinical microbiology. Julio

de 2013. Volumen: 51 Número: 7 Páginas: 2124-30.

• Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and
increased survival in a new murine experimental model of active tuberculosis.

VilAPlAnA c, MArZo e, tAPiA g, diAZ J, gArcíA V, cArdonA PJ The Journal of infectious

diseases. 15 de julio de 2013 Volumen: 208 Número: 2 Páginas: 199-202.
ó

ó

Spin-off:

• Creacin de una spin-off (MANREMYC. Manresana de Microbiologia SL) con
vistas a la comercializacin de un nuevo prebiótico que puede permitir acortar

el tratamiento de la infeccin tuberculosa latente.

Fundraising:

• Fondos conseguidos en el 2013 por el PCI de la UE y de agencias nacionales

han sido 1.741.391€

13
20
T
OR
P
RE
L
A
NU
N
A
S /
E
ER
B
CI

49